Drug Profile

NVI 100

Alternative Names: AXN-001; FE-205030; NVI-100

Latest Information Update: 11 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ferring Pharmaceuticals
Developer Nuvie Bio
Class Antimigraines; Peptides
Mechanism of Action Calcitonin gene-related peptide receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Migraine

Most Recent Events

08 Jan 2025 Nuvie Bio announces intention to submit an Investigational New Drug (IND) application for NVI 100 for the phase II trial in Migraine in 2025
08 Jan 2025 Adverse events and pharmacokinetics data from a phase I trial in Migraine released by Nuvie Bio
08 Jan 2025 Nuvie Bio completes a phase I trial in Migraine (In volunteers) (SC) prior to January 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com